Symbol | Exchange | Currency |
|---|
(Bloomberg) -- Oil fell as traders monitored the worsening fallout from the closure of the largest U.S. oil-products pipeline, and looked ahead to OPEC’s latest analysis of global...
By Gina LeeInvesting.com – Oil was up Friday morning in Asia, set for its second consecutive weekly advance thanks to a broad rally in commodities as well as positive economic...
(Bloomberg) -- Oil headed for a second straight weekly advance as investors bet on rising energy demand amid a broad rally in commodities, with robust trade data from China...
Vanda Pharmaceuticals Inc. (VNDA) is a US biopharma marketer and developer of treatments intended to address specific unmet medical needs. Currently, even stronger demand is...
Menlo Therapeutics Inc. (NASDAQ:MNLO) announced that it has completed patient enrollment in its phase II study evaluating the safety and efficacy of once-daily oral serlopitant...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Buy | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Neutral | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Sell | Neutral | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,272.32 | 2,278.87 | 2,237.66 | -19.43 | -0.85% | 1.18M | NASDAQ | |||
| 305.76 | 306.57 | 299.80 | -0.21 | -0.07% | 13.99M | NASDAQ | |||
| 19.80 | 20.21 | 17.06 | +1.33 | +7.20% | 170.78M | NYSE | |||
| 219.84 | 220.20 | 213.00 | +0.31 | +0.14% | 9.93M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 10.11 | 10.48 | 9.61 | +0.37 | +3.80% | 37.60M | NYSE | |||
| 146.62 | 147.36 | 136.59 | +3.40 | +2.37% | 3.57M | NYSE | |||
| 7.72 | 7.72 | 7.51 | -0.02 | -0.26% | 8.12M | NYSE | |||
| 1.145 | 1.17 | 1.08 | +0.0050 | +0.44% | 8.37M | NYSE | |||
| 22.96 | 23.39 | 18.47 | +2.89 | +14.40% | 64.74M | NASDAQ | |||
| 10.05 | 10.09 | 9.81 | +0.07 | +0.70% | 1.04M | NYSE | |||
| 16.23 | 16.25 | 15.16 | +0.43 | +2.72% | 2.91M | NYSE | |||
| 0.8251 | 0.00 | 0.00 | +0.0096 | +1.18% | 1.26M | NYSE | |||
| 68.52 | 68.62 | 67.09 | +0.01 | +0.01% | 673.44K | NYSE | |||
| 75.10 | 75.54 | 64.87 | +11.10 | +17.34% | 22.62M | NYSE |
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.